tqb3912
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 31, 2023 (NCT05997342)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
MAP3K1 inhibitor
AURKB inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06851442 | Phase 1/Phase 2 (Phase 2) | May 16, 2025 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT05997342 | Phase 1 | Aug 31, 2023 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd | For profit | 2 | 2 | 2 | 2023 |
1 organizations
Page 1 / 1